Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-01-06
2009-08-18
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S250000, C544S251000
Reexamination Certificate
active
07576091
ABSTRACT:
A compound of formula 1, or a pharmaceutically acceptable salt thereof, wherein:X is S, O, or NH; “a” is a single bond; or “a” is a double bond and one of R3and R4, and one of R5and R6are absent; R1is H; or is selected from an alkyl group, a cycloalkyl group, a heteroaryl group, an aralkyl group, CO-alkyl, SO2-alkyl, CO2R13and an aryl group, each of which optionally contains one or more heteroatoms, and is optionally substituted with one or more groups selected from R8and R9; R2is H, R8, or an alkyl group optionally substituted with one or more R8groups; R3, R4, R5, and R6are each independently selected from H, R8, an alkyl group and an alkenyl group, wherein said alkyl and alkenyl groups are optionally substituted with one or more R8groups; or R3and R4, and/or R5and R6together represent ═O; R7is H, R8, NH(CH2)nR9, CO(CH2)nR9, NHCO(CH2)nR9, O(CH2)nR9, or an alkyl or phenyl group, each of which is optionally substituted with one or more groups selected from R8and R9; R8is OR10, NR10R11, halogen, CF3, NO2, COR10, CN, COOR10, CONR10R11, SO2R10or SO2NR10R11; R9is a saturated or unsaturated 5- or 6-membered cyclic group optionally containing one or more heteroatoms selected from N, O and S, and optionally substituted with one or more R8groups; R10, R11, R12and R13are each independently H or a hydrocarbyl group; and n is 0, 1, 2 or 3.Further aspects of the invention relate to pharmaceutical compositions comprising compounds of formula 1, and the therapeutic use thereof in the treatment of proliferative disorders, viral disorders, CNS disorders, diabetes, stroke and cardiovascular disorders.
REFERENCES:
patent: 5679683 (1997-10-01), Bridges et al.
patent: 6531479 (2003-03-01), Wang
patent: 2003/0055068 (2003-03-01), Bebbington
Liu, M.C., et al., Novel Strategies in Cancer Therapeutics: Targeting Enzymes Involved in Cell Cycle Regulation and Cellular Proliferation, Current Cancer Drug Targets, 4, 403-424 (2004).
Mani, et al., Cyclin-dependent Kinase Inhibitors: Novel Anticancer Agents, Exp. Opin. Invest. Drugs 9(8), 1849-70 (2000).
Meijer, L., et al., Roscovitine and Other Purines as Kinase Inhibitors. From Starfish Oocytes to Clinical Trials, Acc. Chem. Res., 36, 417-425 (2003).
Noble, M., Protein Kinase Inhibitors: Insights into Drug Design from Structure, Science, vol. 303, Issue 5665, 1800-1805 (2004).
ATCC No. CCL-185 retrieved online at http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/Default.aspx?ATCCNum=CCL-185&Template=cellBiology (2008).
ATCC No. HTB-38 retrieved online at http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/Default.aspx?ATCCNum=HTB-38&Template=cellBiology (2008).
ATCC No. HTB-85 retrieved online at http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/Default.aspx?ATCCNum=HTB-85&Template=cellBiology (2008).
Newell, “Review of Clinical Trials with Cell Cycle Based Strategies,”Clinical Cancer Research, vol. 7(Suppl.):3822s, No. P825 (2001).
Wu, Su Ying et al., “Discovery of a Novel Family of CDK Inhibitors with the Program LIDAEUS: Structural Basis for Ligand-Induced Disordering of the Activation Loop,”Structure, vol. 11:399-410 (2003).
Showalter, H.D. Hollis et al., “Tyrosine Kinase Inhibitors. 16. 6,5,6-Tricyclic Benzothieno[3,2-d]pyrimidines and Pyrimido[5,4-b]- and -[4,5-b]indoles as Potent Inhibitors of the Epidermal Growth Factor Receptor Tyrosine Kinase,”J. Med. Chem., vol. 42:5464-5474 (1999).
International Search Report for Application No. PCT/GB2004/002935, dated Oct. 5, 2004.
Fischer Peter Martin
McInnes Campbell
McIntyre Neil
Thomas Mark Peter
Wang Shudong
Cyclacel Limited
Kanik Cynthia L.
Lahive & Cockfield LLP
Leeser Erich A
Trinque Brian C.
LandOfFree
Thiazolo-, oxazalo and imidazolo-quinazoline compounds... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thiazolo-, oxazalo and imidazolo-quinazoline compounds..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thiazolo-, oxazalo and imidazolo-quinazoline compounds... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4112698